检验医学与临床
檢驗醫學與臨床
검험의학여림상
JOURNAL OF LABORATORY MEDICINE AND CLINICAL SCIENCES
2014年
16期
2199-2200,2202
,共3页
细胞角蛋白19%肝癌%肝切除术%预后
細胞角蛋白19%肝癌%肝切除術%預後
세포각단백19%간암%간절제술%예후
cytokeratin 19%hepatocellular carcinoma%liver resection%prognosis
目的：探讨细胞角蛋白19（K19）表达对原发性肝癌肝切除术的预后价值。方法对152例肝细胞肝癌（HCC）行手术切除肝组织的患者进行研究，采用免疫组化法评估其肝癌组织中CK19的表达。≥5％的肿瘤细胞中度以上的膜和（或）胞质的表达定义为CK19阳性。结果 CK19阴性的患者术后1年和5年总生存率分别为90．7％和80．4％；CK19阳性组术后1年和5年总生存率分别为66．7％和32．2％，差异具有统计学意义。结论对于原发性肝癌患者，肝癌组织中CK19的表达增加往往表现为手术预后较差。
目的：探討細胞角蛋白19（K19）錶達對原髮性肝癌肝切除術的預後價值。方法對152例肝細胞肝癌（HCC）行手術切除肝組織的患者進行研究，採用免疫組化法評估其肝癌組織中CK19的錶達。≥5％的腫瘤細胞中度以上的膜和（或）胞質的錶達定義為CK19暘性。結果 CK19陰性的患者術後1年和5年總生存率分彆為90．7％和80．4％；CK19暘性組術後1年和5年總生存率分彆為66．7％和32．2％，差異具有統計學意義。結論對于原髮性肝癌患者，肝癌組織中CK19的錶達增加往往錶現為手術預後較差。
목적：탐토세포각단백19（K19）표체대원발성간암간절제술적예후개치。방법대152례간세포간암（HCC）행수술절제간조직적환자진행연구，채용면역조화법평고기간암조직중CK19적표체。≥5％적종류세포중도이상적막화（혹）포질적표체정의위CK19양성。결과 CK19음성적환자술후1년화5년총생존솔분별위90．7％화80．4％；CK19양성조술후1년화5년총생존솔분별위66．7％화32．2％，차이구유통계학의의。결론대우원발성간암환자，간암조직중CK19적표체증가왕왕표현위수술예후교차。
Objective To investigate prognostic value of expression of Cytokeratin (CK) 19 to liver resection for primary hepatic carcinoma .Methods One hundred and fifty two hepatocellular carcinoma (HCC) patients who underwent liver resections were studied .Immunohistochemistry was used to evaluate the expression of Cytokeratin 19 in cancerous tissues .CK19 positivity was defined as membranous and/or cytoplasmic expression in ≥5% of tumor cells with moderate or strong intensity .Results The overall survival (OS) rate of CK19- HCC patients at 1 and 5 years after resections were 90 .7% and 80 .4% ,respectively .OS rate of CK19+ HCC patients at 1 and 5 years after resections were 66 .7% and 32 .2% ,respectively .The difference was significant (P<0 .05) .Conclusion For the pri-mary liver cancer patients ,the increased expression of CK19 in cancerous tissues tends to show poor prognosis .
